akn
Musclechemistry Member
<!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <wunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <woNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <wontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <wontVertAlignCellWithSp/> <wontBreakConstrainedForcedTables/> <wontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> <w:UseFELayout/> </w:Compatibility> <woNotOptimizeForBrowser/> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="--"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--> [FONT="] Description:[/FONT]
[FONT="]Nandrolone undecanoate is an injectable form of the anabolic[/FONT]
[FONT="]steroid nandrolone. The ester applied here is one carbon[/FONT]
[FONT="]atom longer than decanoate, and consequently forms a very[/FONT]
[FONT="]slightly longer-lasting drug deposit at the site of injection.[/FONT]
[FONT="]With proper attention paid to carrier, concentration, volume,[/FONT]
[FONT="]and pharmacokinetics, it would likely even be possible to[/FONT]
[FONT="]formulate this steroid into a very long-acting drug[/FONT]
[FONT="]preparation, one similar to testosterone undecanoate[/FONT]
[FONT="](Nebido) in appearance. Even without a further protracted[/FONT]
[FONT="]therapeutic window, nandrolone undecanoate can be[/FONT]
[FONT="]comfortably injected once every 1 to 2 weeks, which reflects[/FONT]
[FONT="]its slow-acting nature. Although no longer available, this[/FONT]
[FONT="]agent was once highly favored by athletes and bodybuilders[/FONT]
[FONT="]for its ability to promote slow steady gains in lean mass with[/FONT]
[FONT="]minimal estrogenic or androgenic side effects.[/FONT]
[FONT="]History:[/FONT]
[FONT="]Nandrolone undecanoate was developed during the 1960’s,[/FONT]
[FONT="]and was subsequently sold as Dynabolon in Italy (Chrinos)[/FONT]
[FONT="]and France (Theramex), and as Psychobolan in Germany[/FONT]
[FONT="](Theramex). The Italian product was moved to the new[/FONT]
[FONT="]Farmasister label years later, but retained the original[/FONT]
[FONT="]Dynabolon trade name. Dynabolon was generally indicated[/FONT]
[FONT="]for use in patients suffering from malnutrition, catabolic[/FONT]
[FONT="]states, or recovering from major surgery. It was also used to[/FONT]
[FONT="]combat osteoporosis, including the treatment of androgensensitive[/FONT]
[FONT="]populations such as women and the elderly.[/FONT]
[FONT="]Nandrolone undecanoate seems to have exhibited a fair[/FONT]
[FONT="]safety record, yet in spite of this, the three known[/FONT]
[FONT="]commercial preparations did not last on their respective[/FONT]
[FONT="]prescription drug markets. Psychobolan from Germany and[/FONT]
[FONT="]Dynabolon from Farmasister in Italy were discontinued many[/FONT]
[FONT="]years ago, and Dynabolon from France finally followed[/FONT]
[FONT="]before the close of the 1990’s. Presently, no legitimate[/FONT]
[FONT="]pharmaceutical preparation containing nandrolone[/FONT]
[FONT="]undecanoate is known to exist.[/FONT]
[FONT="]How Supplied:[/FONT]
[FONT="]Nandrolone undecanoate is no longer available as a[/FONT]
[FONT="]prescription drug product. When manufactured, it was[/FONT]
[FONT="]supplied at a concentration of 80.5 mg/mL dissolved in oil[/FONT]
[FONT="]and sealed in a 1 mL ampule. Each ampule provided the[/FONT]
[FONT="]equivalent of 50 mg of nandrolone base.[/FONT]
[FONT="]Structural Characteristics:[/FONT]
[FONT="]Nandrolone undecanoate is a modified form of nandrolone,[/FONT]
[FONT="]where a carboxylic acid ester (undecanoic acid) has been[/FONT]
[FONT="]attached to the 17-beta hydroxyl group. Esterified steroids[/FONT]
[FONT="]are less polar than free steroids, and are absorbed more[/FONT]
[FONT="]slowly from the area of injection. Once in the bloodstream,[/FONT]
[FONT="]the ester is removed to yield free (active) nandrolone.[/FONT]
[FONT="]Esterified steroids are designed to prolong the window of[/FONT]
[FONT="]therapeutic effect following administration, allowing for a[/FONT]
[FONT="]less-frequent injection schedule compared to injections of[/FONT]
[FONT="]free (unesterified) steroid. Nandrolone undecanoate is[/FONT]
[FONT="]designed to provide a slow release of nandrolone for up to 3[/FONT]
[FONT="]to 4 weeks following injection.[/FONT]
[FONT="]Side Effects (Estrogenic):[/FONT]
[FONT="]Nandrolone has a low tendency for estrogen conversion,[/FONT]
[FONT="]estimated to be only about 20% of that seen with[/FONT]
[FONT="]testosterone.491 This is because while the liver can convert[/FONT]
[FONT="]nandrolone to estradiol, in other more active sites of steroid[/FONT]
[FONT="]aromatization such as adipose tissue nandrolone is far less[/FONT]
[FONT="]open to this process.492 Consequently, estrogenrelated side[/FONT]
[FONT="]effects are a much lower concern with this drug than with[/FONT]
[FONT="]testosterone. Elevated estrogen levels may still be noticed[/FONT]
[FONT="]with higher dosing, however, and may cause side effects such[/FONT]
[FONT="]as increased water retention, body fat gain, and[/FONT]
[FONT="]gynecomastia. An anti-estrogen such as clomiphene citrate or[/FONT]
[FONT="]tamoxifen citrate may be necessary to prevent estrogenic side[/FONT]
[FONT="]effects if they occur. One may alternately use an aromatase[/FONT]
[FONT="]inhibitor like Arimidex® (anastrozole), which more[/FONT]
[FONT="]efficiently controls estrogen by preventing its synthesis.[/FONT]
[FONT="]Aromatase inhibitors can be quite expensive in comparison[/FONT]
[FONT="]to anti-estrogens, however, and may also have negative[/FONT]
[FONT="]effects on blood lipids.[/FONT]
[FONT="]It is of note that nandrolone has some activity as a progestin[/FONT]
[FONT="]in the body.493 Although progesterone is a c-19 steroid,[/FONT]
[FONT="]removal of this group as in 19-norprogesterone creates a[/FONT]
[FONT="]hormone with greater binding affinity for its corresponding[/FONT]
[FONT="]receptor. Sharing this trait, many 19-nor anabolic steroids[/FONT]
[FONT="]are shown to have some affinity for the progesterone receptor[/FONT]
[FONT="]as well.494 The side effects associated with progesterone are[/FONT]
[FONT="]similar to those of estrogen, including negative feedback[/FONT]
[FONT="]inhibition of testosterone production and enhanced rate of fat[/FONT]
[FONT="]storage. Progestins also augment the stimulatory effect of[/FONT]
[FONT="]estrogens on mammary tissue growth. There appears to be a[/FONT]
[FONT="]strong synergy between these two hormones here, such that[/FONT]
[FONT="]gynecomastia might even occur with the help of progestins,[/FONT]
[FONT="]without excessive estrogen levels. The use of an antiestrogen,[/FONT]
[FONT="]which inhibits the estrogenic component of this[/FONT]
[FONT="]disorder, is often sufficient to mitigate gynecomastia caused[/FONT]
[FONT="]by nandrolone.[/FONT]
[FONT="]Side Effects (Androgenic):[/FONT]
[FONT="]Although classified as an anabolic steroid, androgenic side[/FONT]
[FONT="]effects are still possible with this substance, especially with[/FONT]
[FONT="]higher doses. This may include bouts of oily skin, acne, and[/FONT]
[FONT="]body/facial hair growth. Anabolic/androgenic steroids may[/FONT]
[FONT="]also aggravate male pattern hair loss. Women are warned of[/FONT]
[FONT="]the potential virilizing effects of anabolic/androgenic[/FONT]
[FONT="]steroids. These may include a deepening of the voice,[/FONT]
[FONT="]menstrual irregularities, changes in skin texture, facial hair[/FONT]
[FONT="]growth, and clitoral enlargement. Nandrolone is a steroid[/FONT]
[FONT="]with relatively low androgenic activity relative to its tissuebuilding[/FONT]
[FONT="]actions, making the threshold for strong androgenic[/FONT]
[FONT="]side effects comparably higher than with more androgenic[/FONT]
[FONT="]agents such as testosterone, methandrostenolone, or[/FONT]
[FONT="]fluoxymesterone. It is also important to point out that due to[/FONT]
[FONT="]its mild androgenic nature and ability to suppress[/FONT]
[FONT="]endogenous testosterone, nandrolone is prone to interfering[/FONT]
[FONT="]with libido in males when used without another androgen.[/FONT]
[FONT="]Note that in androgen-responsive target tissues such as the[/FONT]
[FONT="]skin, scalp, and prostate, the relative androgenicity of[/FONT]
[FONT="]nandrolone is reduced by its reduction to dihydronandrolone[/FONT]
[FONT="](DHN).495 496 The 5-alpha reductase enzyme is responsible[/FONT]
[FONT="]for this metabolism of nandrolone. The concurrent use of a 5-[/FONT]
[FONT="]alpha reductase inhibitor such as finasteride or dutasteride[/FONT]
[FONT="]will interfere with site-specific reduction of nandrolone[/FONT]
[FONT="]action, considerably increasing the tendency of nandrolone to[/FONT]
[FONT="]produce androgenic side effects. Reductase inhibitors should[/FONT]
[FONT="]be avoided with nandrolone if low androgenicity is desired.[/FONT]
[FONT="]Side Effects (Hepatotoxicity):[/FONT]
[FONT="]Nandrolone is not c-17 alpha alkylated, and not known to[/FONT]
[FONT="]have hepatotoxic effects. Liver toxicity is unlikely.[/FONT]
[FONT="]Side Effects (Cardiovascular):[/FONT]
[FONT="]Anabolic/androgenic steroids can have deleterious effects on[/FONT]
[FONT="]serum cholesterol. This includes a tendency to reduce HDL[/FONT]
[FONT="](good) cholesterol values and increase LDL (bad)[/FONT]
[FONT="]cholesterol values, which may shift the HDL to LDL balance[/FONT]
[FONT="]in a direction that favors greater risk of arteriosclerosis. The[/FONT]
[FONT="]relative impact of an anabolic/androgenic steroid on serum[/FONT]
[FONT="]lipids is dependant on the dose, route of administration (oral[/FONT]
[FONT="]vs. injectable), type of steroid (aromatizable or non[/FONT]
[FONT="]aromatizable), and level of resistance to hepatic metabolism.[/FONT]
[FONT="]Studies administering 600 mg of nandrolone decanoate per[/FONT]
[FONT="]week for 10 weeks demonstrated a 26% reduction in HDL[/FONT]
[FONT="]cholesterol levels.497 This suppression is slightly greater[/FONT]
[FONT="]than that reported with an equal dose of testosterone[/FONT]
[FONT="]enanthate, and is in agreement with earlier studies showing a[/FONT]
[FONT="]slightly stronger negative impact on HDL/LDL ratio with[/FONT]
[FONT="]nandrolone decanoate as compared to testosterone[/FONT]
[FONT="]cypionate.498 Nandrolone injectables, however, should still[/FONT]
[FONT="]have a significantly weaker impact on serum lipids than c-17[/FONT]
[FONT="]alpha alkylated agents. Anabolic/androgenic steroids may[/FONT]
[FONT="]also adversely affect blood pressure and triglycerides,[/FONT]
[FONT="]reduce endothelial relaxation, and support left ventricular[/FONT]
[FONT="]hypertrophy, all potentially increasing the risk of[/FONT]
[FONT="]cardiovascular disease and myocardial infarction.[/FONT]
[FONT="]To help reduce cardiovascular strain it is advised to[/FONT]
[FONT="]maintain an active cardiovascular exercise program and[/FONT]
[FONT="]minimize the intake of saturated fats, cholesterol, and simple[/FONT]
[FONT="]carbohydrates at all times during active AAS administration.[/FONT]
[FONT="]Supplementing with fish oils (4 grams per day) and a natural[/FONT]
[FONT="]cholesterol/antioxidant formula such as Lipid Stabil or a[/FONT]
[FONT="]product with comparable ingredients is also recommended.[/FONT]
[FONT="]Side Effects (Testosterone Suppression):[/FONT]
[FONT="]All anabolic/androgenic steroids when taken in doses[/FONT]
[FONT="]sufficient to promote muscle gain are expected to suppress[/FONT]
[FONT="]endogenous testosterone production. For sake of comparison,[/FONT]
[FONT="]studies administering 100 mg per week of nandrolone[/FONT]
[FONT="]decanoate for 6 weeks have demonstrated an approximate[/FONT]
[FONT="]57% reduction in serum testosterone levels during therapy.[/FONT]
[FONT="]At a dosage of 300 mg per week, this reduction reached[/FONT]
[FONT="]70%.499 It is believed that the progestational activity of[/FONT]
[FONT="]nandrolone notably contributes to the suppression of[/FONT]
[FONT="]testosterone synthesis during therapy, which can be marked[/FONT]
[FONT="]in spite of a low tendency for estrogen conversion.500[/FONT]
[FONT="]Without the intervention of testosterone-stimulating[/FONT]
[FONT="]substances, testosterone levels should return to normal within[/FONT]
[FONT="]2-6 months of drug secession. Note that prolonged[/FONT]
[FONT="]hypogonadotrophic hypogonadism can develop secondary to[/FONT]
[FONT="]steroid abuse, necessitating medical intervention.[/FONT]
[FONT="] [/FONT]
[FONT="]Administration (Men):[/FONT]
[FONT="]Nandrolone undecanoate was used clinically at a dose of 1[/FONT]
[FONT="]ampule every 1 to 2 weeks. A total of 3 to 6 ampules were[/FONT]
[FONT="]used for a given 6-week period of therapy. When used for[/FONT]
[FONT="]physique- or performance-enhancing purposes, a dose of 3 to[/FONT]
[FONT="]4 ampules (241.5 to 322mg) per week is most common, taken[/FONT]
[FONT="]in cycles 8 to 12 weeks in length. This level is sufficient for[/FONT]
[FONT="]most users to notice measurable gains in lean muscle mass[/FONT]
[FONT="]and strength, which should be accompanied by a low level of[/FONT]
[FONT="]estrogenic and androgenic activity. Higher doses (400-600[/FONT]
[FONT="]mg per week) will impart a stronger anabolic effect, but can[/FONT]
[FONT="]be difficult given the relatively low concentration this steroid[/FONT]
[FONT="]was manufactured in. Instead, many opted to combine this[/FONT]
[FONT="]agent with other anabolic/androgenic steroids for a stronger[/FONT]
[FONT="]effect. Given its properties, it seems to fit well for both[/FONT]
[FONT="]bulking and cutting purposes, and can reasonably replace[/FONT]
[FONT="]Deca-Durabolin in such cycles.[/FONT]
[FONT="]Administration (Women):[/FONT]
[FONT="]Nandrolone undecanoate was used clinically at a dose of 1[/FONT]
[FONT="]ampule every 1 to 2 weeks. A total of 3 to 6 ampules were[/FONT]
[FONT="]used for a given 6-week period of therapy. When used for[/FONT]
[FONT="]physique- or performance-enhancing purposes, a dosage of 1[/FONT]
[FONT="]ampule (80.5 mg) every 10 days was most common, which is[/FONT]
[FONT="]taken for 4 to 6 weeks. Although only slightly androgenic,[/FONT]
[FONT="]women are occasionally confronted with virilization[/FONT]
[FONT="]symptoms when taking this compound. Should virilizing side[/FONT]
[FONT="]effects become a concern, the drug should be discontinued[/FONT]
[FONT="]immediately to help prevent their permanent appearance.[/FONT]
[FONT="]After a sufficient period of withdrawal, the shorter acting[/FONT]
[FONT="]nandrolone Durabolin® might be considered a safer (more[/FONT]
[FONT="]controllable) option. This drug stays active for only several[/FONT]
[FONT="]days, greatly reducing the withdrawal time if indicated.[/FONT]
[FONT="]Availability:[/FONT]
[FONT="]Nandrolone undecanoate is no longer available as a[/FONT]
[FONT="]prescription drug product. Some underground preparations[/FONT]
[FONT="]are, however, known to exist.
By WL
[/FONT][FONT="][/FONT]
<!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->
[FONT="]Nandrolone undecanoate is an injectable form of the anabolic[/FONT]
[FONT="]steroid nandrolone. The ester applied here is one carbon[/FONT]
[FONT="]atom longer than decanoate, and consequently forms a very[/FONT]
[FONT="]slightly longer-lasting drug deposit at the site of injection.[/FONT]
[FONT="]With proper attention paid to carrier, concentration, volume,[/FONT]
[FONT="]and pharmacokinetics, it would likely even be possible to[/FONT]
[FONT="]formulate this steroid into a very long-acting drug[/FONT]
[FONT="]preparation, one similar to testosterone undecanoate[/FONT]
[FONT="](Nebido) in appearance. Even without a further protracted[/FONT]
[FONT="]therapeutic window, nandrolone undecanoate can be[/FONT]
[FONT="]comfortably injected once every 1 to 2 weeks, which reflects[/FONT]
[FONT="]its slow-acting nature. Although no longer available, this[/FONT]
[FONT="]agent was once highly favored by athletes and bodybuilders[/FONT]
[FONT="]for its ability to promote slow steady gains in lean mass with[/FONT]
[FONT="]minimal estrogenic or androgenic side effects.[/FONT]
[FONT="]History:[/FONT]
[FONT="]Nandrolone undecanoate was developed during the 1960’s,[/FONT]
[FONT="]and was subsequently sold as Dynabolon in Italy (Chrinos)[/FONT]
[FONT="]and France (Theramex), and as Psychobolan in Germany[/FONT]
[FONT="](Theramex). The Italian product was moved to the new[/FONT]
[FONT="]Farmasister label years later, but retained the original[/FONT]
[FONT="]Dynabolon trade name. Dynabolon was generally indicated[/FONT]
[FONT="]for use in patients suffering from malnutrition, catabolic[/FONT]
[FONT="]states, or recovering from major surgery. It was also used to[/FONT]
[FONT="]combat osteoporosis, including the treatment of androgensensitive[/FONT]
[FONT="]populations such as women and the elderly.[/FONT]
[FONT="]Nandrolone undecanoate seems to have exhibited a fair[/FONT]
[FONT="]safety record, yet in spite of this, the three known[/FONT]
[FONT="]commercial preparations did not last on their respective[/FONT]
[FONT="]prescription drug markets. Psychobolan from Germany and[/FONT]
[FONT="]Dynabolon from Farmasister in Italy were discontinued many[/FONT]
[FONT="]years ago, and Dynabolon from France finally followed[/FONT]
[FONT="]before the close of the 1990’s. Presently, no legitimate[/FONT]
[FONT="]pharmaceutical preparation containing nandrolone[/FONT]
[FONT="]undecanoate is known to exist.[/FONT]
[FONT="]How Supplied:[/FONT]
[FONT="]Nandrolone undecanoate is no longer available as a[/FONT]
[FONT="]prescription drug product. When manufactured, it was[/FONT]
[FONT="]supplied at a concentration of 80.5 mg/mL dissolved in oil[/FONT]
[FONT="]and sealed in a 1 mL ampule. Each ampule provided the[/FONT]
[FONT="]equivalent of 50 mg of nandrolone base.[/FONT]
[FONT="]Structural Characteristics:[/FONT]
[FONT="]Nandrolone undecanoate is a modified form of nandrolone,[/FONT]
[FONT="]where a carboxylic acid ester (undecanoic acid) has been[/FONT]
[FONT="]attached to the 17-beta hydroxyl group. Esterified steroids[/FONT]
[FONT="]are less polar than free steroids, and are absorbed more[/FONT]
[FONT="]slowly from the area of injection. Once in the bloodstream,[/FONT]
[FONT="]the ester is removed to yield free (active) nandrolone.[/FONT]
[FONT="]Esterified steroids are designed to prolong the window of[/FONT]
[FONT="]therapeutic effect following administration, allowing for a[/FONT]
[FONT="]less-frequent injection schedule compared to injections of[/FONT]
[FONT="]free (unesterified) steroid. Nandrolone undecanoate is[/FONT]
[FONT="]designed to provide a slow release of nandrolone for up to 3[/FONT]
[FONT="]to 4 weeks following injection.[/FONT]
[FONT="]Side Effects (Estrogenic):[/FONT]
[FONT="]Nandrolone has a low tendency for estrogen conversion,[/FONT]
[FONT="]estimated to be only about 20% of that seen with[/FONT]
[FONT="]testosterone.491 This is because while the liver can convert[/FONT]
[FONT="]nandrolone to estradiol, in other more active sites of steroid[/FONT]
[FONT="]aromatization such as adipose tissue nandrolone is far less[/FONT]
[FONT="]open to this process.492 Consequently, estrogenrelated side[/FONT]
[FONT="]effects are a much lower concern with this drug than with[/FONT]
[FONT="]testosterone. Elevated estrogen levels may still be noticed[/FONT]
[FONT="]with higher dosing, however, and may cause side effects such[/FONT]
[FONT="]as increased water retention, body fat gain, and[/FONT]
[FONT="]gynecomastia. An anti-estrogen such as clomiphene citrate or[/FONT]
[FONT="]tamoxifen citrate may be necessary to prevent estrogenic side[/FONT]
[FONT="]effects if they occur. One may alternately use an aromatase[/FONT]
[FONT="]inhibitor like Arimidex® (anastrozole), which more[/FONT]
[FONT="]efficiently controls estrogen by preventing its synthesis.[/FONT]
[FONT="]Aromatase inhibitors can be quite expensive in comparison[/FONT]
[FONT="]to anti-estrogens, however, and may also have negative[/FONT]
[FONT="]effects on blood lipids.[/FONT]
[FONT="]It is of note that nandrolone has some activity as a progestin[/FONT]
[FONT="]in the body.493 Although progesterone is a c-19 steroid,[/FONT]
[FONT="]removal of this group as in 19-norprogesterone creates a[/FONT]
[FONT="]hormone with greater binding affinity for its corresponding[/FONT]
[FONT="]receptor. Sharing this trait, many 19-nor anabolic steroids[/FONT]
[FONT="]are shown to have some affinity for the progesterone receptor[/FONT]
[FONT="]as well.494 The side effects associated with progesterone are[/FONT]
[FONT="]similar to those of estrogen, including negative feedback[/FONT]
[FONT="]inhibition of testosterone production and enhanced rate of fat[/FONT]
[FONT="]storage. Progestins also augment the stimulatory effect of[/FONT]
[FONT="]estrogens on mammary tissue growth. There appears to be a[/FONT]
[FONT="]strong synergy between these two hormones here, such that[/FONT]
[FONT="]gynecomastia might even occur with the help of progestins,[/FONT]
[FONT="]without excessive estrogen levels. The use of an antiestrogen,[/FONT]
[FONT="]which inhibits the estrogenic component of this[/FONT]
[FONT="]disorder, is often sufficient to mitigate gynecomastia caused[/FONT]
[FONT="]by nandrolone.[/FONT]
[FONT="]Side Effects (Androgenic):[/FONT]
[FONT="]Although classified as an anabolic steroid, androgenic side[/FONT]
[FONT="]effects are still possible with this substance, especially with[/FONT]
[FONT="]higher doses. This may include bouts of oily skin, acne, and[/FONT]
[FONT="]body/facial hair growth. Anabolic/androgenic steroids may[/FONT]
[FONT="]also aggravate male pattern hair loss. Women are warned of[/FONT]
[FONT="]the potential virilizing effects of anabolic/androgenic[/FONT]
[FONT="]steroids. These may include a deepening of the voice,[/FONT]
[FONT="]menstrual irregularities, changes in skin texture, facial hair[/FONT]
[FONT="]growth, and clitoral enlargement. Nandrolone is a steroid[/FONT]
[FONT="]with relatively low androgenic activity relative to its tissuebuilding[/FONT]
[FONT="]actions, making the threshold for strong androgenic[/FONT]
[FONT="]side effects comparably higher than with more androgenic[/FONT]
[FONT="]agents such as testosterone, methandrostenolone, or[/FONT]
[FONT="]fluoxymesterone. It is also important to point out that due to[/FONT]
[FONT="]its mild androgenic nature and ability to suppress[/FONT]
[FONT="]endogenous testosterone, nandrolone is prone to interfering[/FONT]
[FONT="]with libido in males when used without another androgen.[/FONT]
[FONT="]Note that in androgen-responsive target tissues such as the[/FONT]
[FONT="]skin, scalp, and prostate, the relative androgenicity of[/FONT]
[FONT="]nandrolone is reduced by its reduction to dihydronandrolone[/FONT]
[FONT="](DHN).495 496 The 5-alpha reductase enzyme is responsible[/FONT]
[FONT="]for this metabolism of nandrolone. The concurrent use of a 5-[/FONT]
[FONT="]alpha reductase inhibitor such as finasteride or dutasteride[/FONT]
[FONT="]will interfere with site-specific reduction of nandrolone[/FONT]
[FONT="]action, considerably increasing the tendency of nandrolone to[/FONT]
[FONT="]produce androgenic side effects. Reductase inhibitors should[/FONT]
[FONT="]be avoided with nandrolone if low androgenicity is desired.[/FONT]
[FONT="]Side Effects (Hepatotoxicity):[/FONT]
[FONT="]Nandrolone is not c-17 alpha alkylated, and not known to[/FONT]
[FONT="]have hepatotoxic effects. Liver toxicity is unlikely.[/FONT]
[FONT="]Side Effects (Cardiovascular):[/FONT]
[FONT="]Anabolic/androgenic steroids can have deleterious effects on[/FONT]
[FONT="]serum cholesterol. This includes a tendency to reduce HDL[/FONT]
[FONT="](good) cholesterol values and increase LDL (bad)[/FONT]
[FONT="]cholesterol values, which may shift the HDL to LDL balance[/FONT]
[FONT="]in a direction that favors greater risk of arteriosclerosis. The[/FONT]
[FONT="]relative impact of an anabolic/androgenic steroid on serum[/FONT]
[FONT="]lipids is dependant on the dose, route of administration (oral[/FONT]
[FONT="]vs. injectable), type of steroid (aromatizable or non[/FONT]
[FONT="]aromatizable), and level of resistance to hepatic metabolism.[/FONT]
[FONT="]Studies administering 600 mg of nandrolone decanoate per[/FONT]
[FONT="]week for 10 weeks demonstrated a 26% reduction in HDL[/FONT]
[FONT="]cholesterol levels.497 This suppression is slightly greater[/FONT]
[FONT="]than that reported with an equal dose of testosterone[/FONT]
[FONT="]enanthate, and is in agreement with earlier studies showing a[/FONT]
[FONT="]slightly stronger negative impact on HDL/LDL ratio with[/FONT]
[FONT="]nandrolone decanoate as compared to testosterone[/FONT]
[FONT="]cypionate.498 Nandrolone injectables, however, should still[/FONT]
[FONT="]have a significantly weaker impact on serum lipids than c-17[/FONT]
[FONT="]alpha alkylated agents. Anabolic/androgenic steroids may[/FONT]
[FONT="]also adversely affect blood pressure and triglycerides,[/FONT]
[FONT="]reduce endothelial relaxation, and support left ventricular[/FONT]
[FONT="]hypertrophy, all potentially increasing the risk of[/FONT]
[FONT="]cardiovascular disease and myocardial infarction.[/FONT]
[FONT="]To help reduce cardiovascular strain it is advised to[/FONT]
[FONT="]maintain an active cardiovascular exercise program and[/FONT]
[FONT="]minimize the intake of saturated fats, cholesterol, and simple[/FONT]
[FONT="]carbohydrates at all times during active AAS administration.[/FONT]
[FONT="]Supplementing with fish oils (4 grams per day) and a natural[/FONT]
[FONT="]cholesterol/antioxidant formula such as Lipid Stabil or a[/FONT]
[FONT="]product with comparable ingredients is also recommended.[/FONT]
[FONT="]Side Effects (Testosterone Suppression):[/FONT]
[FONT="]All anabolic/androgenic steroids when taken in doses[/FONT]
[FONT="]sufficient to promote muscle gain are expected to suppress[/FONT]
[FONT="]endogenous testosterone production. For sake of comparison,[/FONT]
[FONT="]studies administering 100 mg per week of nandrolone[/FONT]
[FONT="]decanoate for 6 weeks have demonstrated an approximate[/FONT]
[FONT="]57% reduction in serum testosterone levels during therapy.[/FONT]
[FONT="]At a dosage of 300 mg per week, this reduction reached[/FONT]
[FONT="]70%.499 It is believed that the progestational activity of[/FONT]
[FONT="]nandrolone notably contributes to the suppression of[/FONT]
[FONT="]testosterone synthesis during therapy, which can be marked[/FONT]
[FONT="]in spite of a low tendency for estrogen conversion.500[/FONT]
[FONT="]Without the intervention of testosterone-stimulating[/FONT]
[FONT="]substances, testosterone levels should return to normal within[/FONT]
[FONT="]2-6 months of drug secession. Note that prolonged[/FONT]
[FONT="]hypogonadotrophic hypogonadism can develop secondary to[/FONT]
[FONT="]steroid abuse, necessitating medical intervention.[/FONT]
[FONT="] [/FONT]
[FONT="]Administration (Men):[/FONT]
[FONT="]Nandrolone undecanoate was used clinically at a dose of 1[/FONT]
[FONT="]ampule every 1 to 2 weeks. A total of 3 to 6 ampules were[/FONT]
[FONT="]used for a given 6-week period of therapy. When used for[/FONT]
[FONT="]physique- or performance-enhancing purposes, a dose of 3 to[/FONT]
[FONT="]4 ampules (241.5 to 322mg) per week is most common, taken[/FONT]
[FONT="]in cycles 8 to 12 weeks in length. This level is sufficient for[/FONT]
[FONT="]most users to notice measurable gains in lean muscle mass[/FONT]
[FONT="]and strength, which should be accompanied by a low level of[/FONT]
[FONT="]estrogenic and androgenic activity. Higher doses (400-600[/FONT]
[FONT="]mg per week) will impart a stronger anabolic effect, but can[/FONT]
[FONT="]be difficult given the relatively low concentration this steroid[/FONT]
[FONT="]was manufactured in. Instead, many opted to combine this[/FONT]
[FONT="]agent with other anabolic/androgenic steroids for a stronger[/FONT]
[FONT="]effect. Given its properties, it seems to fit well for both[/FONT]
[FONT="]bulking and cutting purposes, and can reasonably replace[/FONT]
[FONT="]Deca-Durabolin in such cycles.[/FONT]
[FONT="]Administration (Women):[/FONT]
[FONT="]Nandrolone undecanoate was used clinically at a dose of 1[/FONT]
[FONT="]ampule every 1 to 2 weeks. A total of 3 to 6 ampules were[/FONT]
[FONT="]used for a given 6-week period of therapy. When used for[/FONT]
[FONT="]physique- or performance-enhancing purposes, a dosage of 1[/FONT]
[FONT="]ampule (80.5 mg) every 10 days was most common, which is[/FONT]
[FONT="]taken for 4 to 6 weeks. Although only slightly androgenic,[/FONT]
[FONT="]women are occasionally confronted with virilization[/FONT]
[FONT="]symptoms when taking this compound. Should virilizing side[/FONT]
[FONT="]effects become a concern, the drug should be discontinued[/FONT]
[FONT="]immediately to help prevent their permanent appearance.[/FONT]
[FONT="]After a sufficient period of withdrawal, the shorter acting[/FONT]
[FONT="]nandrolone Durabolin® might be considered a safer (more[/FONT]
[FONT="]controllable) option. This drug stays active for only several[/FONT]
[FONT="]days, greatly reducing the withdrawal time if indicated.[/FONT]
[FONT="]Availability:[/FONT]
[FONT="]Nandrolone undecanoate is no longer available as a[/FONT]
[FONT="]prescription drug product. Some underground preparations[/FONT]
[FONT="]are, however, known to exist.
By WL
[/FONT][FONT="][/FONT]
<!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->